LexBio Partners with Hiteck Biopharma – AI-Enabled Drug Discovery Alliance Targets Inflammatory Disease Small Molecules
Suzhou Langrui Biopharmaceutical Co., Ltd. (LexBio), an AI-enabled drug development biotech, announced a strategic partnership...
Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers
Chongqing Maile Bio-Pharm Co. Ltd. and Shenzhen Main Luck Pharmaceuticals Inc. announced a strategic partnership...
Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with...
Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface
Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...
Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases
Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...
Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials
Qilu Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 innovative drug, QLS1317 tablets, has...
NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation
China’s National Healthcare Security Administration (NHSA) held a briefing outlining the DRG (Diagnosis‑Related Groups) Grouping...
Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has entered into a strategic partnership...
Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD
Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp...
Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India
Bio‑Thera Solutions Inc. (SHA: 688177) has expanded its strategic partnership with Intas Pharmaceuticals Ltd., granting...
Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network
Sanofi S.A. (NASDAQ: SNY) announced a comprehensive strategic upgrade of its China R&D center, establishing...
RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced NMPA approval for a new indication of...
Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push
Novartis AG (NYSE: NVS) announced at the China Development Forum (CDF) 2026 Annual Meeting that...
Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that HLX18, a recombinant humanized anti‑PD‑1 monoclonal antibody...
Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China
Everest Medicines Limited (HKG: 1952) has entered into an asset acquisition agreement with Corxel Pharmaceuticals...
Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic
Lepu Biopharma Co., Ltd. (HKG: 2157) announced NMPA IND approval for a groundbreaking Phase II/III...
Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5%...
Biokin Pharma’s BL‑ARC002 Wins NMPA Approval – First‑in‑Class Antibody‑Radionuclide Conjugate Enters Solid Tumor Trials
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL‑ARC002 injection, a Category 1...
Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have...
Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer
Novartis AG (NYSE: NVS) announced a definitive agreement to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor,...